The impact of eligibility for maintenance immunotherapy on prognosis in patients with unresectable or metastatic urothelial carcinoma.
chemotherapy
maintenance immunotherapy
prognosis
radiological response
urothelial carcinoma
Journal
BJUI compass
ISSN: 2688-4526
Titre abrégé: BJUI Compass
Pays: United States
ID NLM: 101764975
Informations de publication
Date de publication:
Mar 2022
Mar 2022
Historique:
received:
27
05
2021
revised:
09
09
2021
accepted:
09
09
2021
entrez:
27
4
2022
pubmed:
28
4
2022
medline:
28
4
2022
Statut:
epublish
Résumé
To investigate the eligibility for maintenance immunotherapy and its impact on the prognosis of advanced urothelial carcinoma treated with first-line chemotherapy, as the selection biases of the eligible population in the JAVELIN Bladder 100 trial remain unclear. We retrospectively evaluated 213 patients (median age, 71 years) with unresectable locally advanced or metastatic urothelial carcinoma treated with platinum-based first-line chemotherapy between May 2003 and April 2021. The patients were categorized into the following two groups: progressive disease (PD) within four cycles (trial ineligible group) and non-PD within four cycles (trial eligible group). The primary outcomes were the estimated proportion of trial eligible patients for maintenance immunotherapy. The secondary outcomes were the comparison of the overall survival in the trial eligible and ineligible groups and the impact of radiologic response at the second cycle on the fourth cycle. Among the 213 patients, 81 (38%) were included in the trial eligible group. The trial eligible group had a significantly longer overall survival than the trial ineligible group ( We observed 38% of the trial eligible population. Overall survival was significantly different between the trial eligible and ineligible groups.
Identifiants
pubmed: 35474727
doi: 10.1002/bco2.119
pii: BCO2119
pmc: PMC8988805
doi:
Types de publication
Journal Article
Langues
eng
Pagination
139-145Informations de copyright
© 2021 The Authors. BJUI Compass published by John Wiley & Sons Ltd on behalf of BJU International Company.
Déclaration de conflit d'intérêts
The authors have no conflict of interest.
Références
Lancet Oncol. 2020 Dec;21(12):1574-1588
pubmed: 32971005
Nat Commun. 2020 Dec 2;11(1):6175
pubmed: 33268821
Cell Death Dis. 2020 Nov 26;11(11):1013
pubmed: 33243969
Cancer Treat Rev. 2021 Jun;97:102187
pubmed: 33839438
World J Urol. 2016 Jan;34(1):3-11
pubmed: 26497825
J Urol. 2018 Dec;200(6):1207-1214
pubmed: 30012366
Int J Clin Oncol. 2017 Apr;22(2):366-372
pubmed: 27933402
Clin Genitourin Cancer. 2018 Aug;16(4):e879-e892
pubmed: 29576445
Eur Urol Focus. 2019 Nov;5(6):1066-1073
pubmed: 29548907
Int J Urol. 2020 Sep;27(9):702-709
pubmed: 32564429
J Clin Oncol. 2012 Jan 10;30(2):191-9
pubmed: 22162575
N Engl J Med. 2020 Sep 24;383(13):1218-1230
pubmed: 32945632
Int J Clin Oncol. 2018 Aug;23(4):599-607
pubmed: 29556919
Urol Oncol. 2021 Dec;39(12):832.e17-832.e23
pubmed: 33865689
Stat Med. 2015 Dec 10;34(28):3661-79
pubmed: 26238958
J Clin Oncol. 2005 Jul 20;23(21):4602-8
pubmed: 16034041
BJUI Compass. 2021 Oct 08;3(2):139-145
pubmed: 35474727
Int J Clin Oncol. 2015 Apr;20(2):369-74
pubmed: 24865474
Lancet Oncol. 2011 Mar;12(3):211-4
pubmed: 21376284
Eur Urol. 2018 Apr;73(4):560-569
pubmed: 29325693
Lancet. 2017 Jan 7;389(10064):67-76
pubmed: 27939400
Eur Urol. 2021 Jan;79(1):82-104
pubmed: 32360052
Int J Clin Oncol. 2021 Jan;26(1):154-162
pubmed: 33067647
J Natl Compr Canc Netw. 2018 Sep;16(9):1041-1053
pubmed: 30181416
J Clin Oncol. 2011 Jun 10;29(17):2432-8
pubmed: 21555688
Int J Urol. 2021 Sep;28(9):970-974
pubmed: 34240471
J Clin Oncol. 2012 Apr 1;30(10):1107-13
pubmed: 22370319
Eur Urol. 2016 Apr;69(4):634-641
pubmed: 26264159
Int J Urol. 2021 Sep;28(9):899-905
pubmed: 34028105